Glycated human serum albumin (Amadori product) (GHSA (Amadori))

Glycated human serum albumin (Amadori product), often referred to as Amadori-glycated albumin, results from the early non-enzymatic glycation of albumin, where reducing sugars such as glucose form a Schiff base with lysine residues on albumin, which rearranges into a more stable Amadori product (fructosamine)[1][2][3]. This process is accelerated in diabetes mellitus and serves both as an intermediate biomarker for hyperglycemia and as a contributor to diabetic complications such as nephropathy by altering albumin's biological and structural properties[1][2]. Although it is not a classical therapeutic target such as a receptor, enzyme, or transporter, Amadori-glycated albumin plays an important role in pathophysiology and is used as a diagnostic biomarker in clinical practice[1][2][3]. Notes: - "Amadori-glycated albumin" is not a traditional therapeutic target but a biochemical modification and a clinical biomarker. - This concept may be considered "incorrect" as a classical drug target since most interventions aim to prevent its formation or use it as a disease biomarker, not to directly modulate it as a receptor or enzyme. - No conventional drugs directly bind or modulate Amadori products as their primary mechanism. - Amadori products are distinct from advanced glycation end products (AGEs), which may have their own receptors (e.g., RAGE).

Other names

Amadori-glycated albuminGlycated albumin (Amadori product)GHSA (Amadori)

Inhibitors like aminoguanidine and pyridoxamine prevent non-enzymatic glycation of proteins[1]. AGE breakers (e.g., ALT-711) disrupt cross-links formed after glycation[1].